Results 1 to 10 of about 58,085 (295)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid [PDF]

Frontiers in Immunology, 2019
Bullous pemphigoid (BP) is an organ-specific autoantibody-mediated blistering skin disease that mainly affects the elderly. Typical clinical features include the widespread blisters, often preceded by and/or associated with itchy urticarial or eczema ...
Kaisa Tasanen, Outi Varpuluoma, Wataru Nishie   +2 more
doaj   +6 more sources

Association of dipeptidyl peptidase‐4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan [PDF]

Journal of Diabetes Investigation, 2023
Aims/Introduction This study was designed and carried out to investigate the association of dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use with pancreatic cancer (PC) in individuals with diabetes in Japan.
Sodai Kubota, Takuya Haraguchi, Hitoshi Kuwata, Yusuke Seino, Kenta Murotani, Takumi Tajima, Gen Terashima, Makiko Kaneko, Yoshihiro Takahashi, Ken Takao, Takehiro Kato, Kenichiro Shide, Saeko Imai, Atsushi Suzuki, Yasuo Terauchi, Yuichiro Yamada, Yutaka Seino, Daisuke Yabe   +17 more
doaj   +3 more sources

Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer’s disease: a narrative review [PDF]

Frontiers in Pharmacology
Insulin resistance in brain and amyloidogenesis are principal pathological features of diabetes-related cognitive decline and development of Alzheimer’s disease (AD).
Xin Jiang, Ji Li, Xiaohui Yao, Hao Ding, Aihong Gu, Zhen Zhou   +5 more
doaj   +3 more sources

Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes ( CVD‐REAL Nordic ) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study [PDF]

Diabetes, obesity and metabolism, 2017
To compare the sodium‐glucose‐cotransporter‐2 (SGLT‐2) inhibitor dapagliflozin with dipeptidyl peptidase‐4 (DPP‐4) inhibitors with regard to risk associations with major adverse cardiovascular (CV) events (MACE; non‐fatal myocardial infarction, non‐fatal
Frederik Persson, Thomas Nyström, Marit E. Jørgensen, Bendix Carstensen, Hanne L. Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Jan W. Eriksson, Anna Norhammar, Johan Bodegård, Kåre I. Birkeland   +11 more
openalex   +2 more sources

Cardioprotective effects of sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase 4 inhibitor in type 2 diabetes: A meta-analysis of comparative safety and efficacy [PDF]

SAGE Open Medicine
Background: Sodium glucose cotransporter 2 inhibitors are recommended for the treatment of heart failure due to their cardioprotective effects, despite primarily being used as antidiabetic medications. However, the comparative profile of two antidiabetic
Abhigan Babu Shrestha, Anupam Halder, Kripa Rajak, Saroj Kumar Jha, Ramesh Lamichhane, Arefin Naher Oishee, Nayanika Tummala Chowdary, Pashupati Pokharel, Sajina Shrestha, Lukash Adhikari, Bikash Adhikari, Aman Rajak, Jalal Haider Khan, Nischal Mainali   +13 more
doaj   +2 more sources

Ocular cicatricial pemphigoid following Dipeptidyl Peptidase-4 inhibitor use: A case report [PDF]

American Journal of Ophthalmology Case Reports, 2023
Purpose: To report a rare Ocular Cicatricial Pemphigoid (OCP) case in a patient taking a Dipeptidyl Peptidase-4 Inhibitor (DPP-4 inhibitor), a medication used for the management of type 2 diabetes, for at least six years. Observations: A 64-year-old male
Akifumi Matsumoto, Hideki Fukuoka, Akiko Yoneda, Norihiko Yokoi, Chie Sotozono   +4 more
doaj   +2 more sources

Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation [PDF]

Scientific Reports, 2016
The inhibitors of CD26 (dipeptidyl peptidase-4; DPP4) have been widely prescribed to control glucose level in diabetic patients. DPP4-inhibitors, however, accumulate stromal cell-derived factor-1α (SDF-1α), a well-known inducer of vascular leakage and ...
Choon-Soo Lee, Yun Gi Kim, Hyun‐Jai Cho, Jonghanne Park, Heewon Jeong, Sang‐Eun Lee, Seung‐Pyo Lee, Hyun‐Jae Kang, Hyo‐Soo Kim   +8 more
openalex   +2 more sources

Novel Dipeptidyl Peptidase-4–Inhibiting Peptide Derived From β-Lactoglobulin

Journal of Pharmacological Sciences, 2011
.: Trypsin-treated β-lactoglobulin significantly decreased the glucose level after an oral glucose tolerance test using mice. We performed the present study to identify the active peptide inhibiting dipeptidyl peptidase-4 from trypsin-treated β ...
Masayuki Uchida, Yukio Ohshiba, Orie Mogami   +2 more
doaj   +3 more sources

Evaluation of dipeptidyl peptidase-4 inhibitor-associated gastrointestinal symptoms using the prescription claims database. [PDF]

Sci Rep
Funabashi A, Ito H, Maeda M, Hasegawa Y, Tsukioka R, Onda M.   +5 more
europepmc   +3 more sources

Severe edema and blood blisters of the lower extremities caused by sitagliptin, a dipeptidyl peptidase‐4 inhibitor [PDF]

Journal of General and Family Medicine, 2022
Hiroki Maita, Tadashi Kobayashi, Takashi Akimoto, Hiroshi Osawa, Hiroyuki Kato   +4 more
doaj   +2 more sources